Lisata Therapeutics, Inc. (FRA:8NE)
Germany · Delayed Price · Currency is EUR 1.690
0.00 (0.00%)
At close: Nov 28, 2025
Lisata Therapeutics Company Description
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases.
Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimens.
The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Lisata Therapeutics, Inc.
| Country | United States |
| Founded | 1980 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 26 |
| CEO | David Mazzo |
Contact Details
Address: 110 Allen Road Basking Ridge, Delaware 07920 United States | |
| Phone | 908 842 0100 |
| Website | lisata.com |
Stock Details
| Ticker Symbol | 8NE |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| David Mazzo | Chief Executive Officer |
| James Nisco | Chief Financial Officer |
| Tariq Imam | Chief Operating Officer |
| John Menditto | Head of Investor Relations |